Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Vetigenics has raised $6.0M in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Vetigenics's investors include Newchip Accelerator.
Vetigenics is headquartered in Philadelphia, United States.
Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Vetigenics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vetigenics — Funding & Investors." VCBacked, February 3, 2025, https://www.vcbacked.co/company/vetigenics. Accessed October 31, 2026.
VCBacked. (2025). Vetigenics — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/vetigenics
{{cite web |title=Vetigenics — Funding & Investors |url=https://www.vcbacked.co/company/vetigenics |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated